Nuage Therapeutics

Nuage Therapeutics is a spin-off from the IRB Barcelona and ICREA. Based at the Barcelona Science Park, Nuage develops drug screening assays to target intrinsically disordered proteins that undergo biomolecular condensation, providing new treatments for diseases currently considered difficult to treat. Part of the technology developed by Nuage Therapeutics was funded by the Asociación Española contra el Cáncer (AECC), through its “AECC Innova” programme, and by ”la Caixa” Foundation, through its CaixaResearch Validate programme.


The Sofinnova Capital Strategy acts as a founding and lead investor in early-stage biopharma and medtech start-ups focusing on groundbreaking therapeutic technologies.

SofinnovaMD Start

The MD Start Strategy is Sofinnova’s in-house medtech accelerator. The team’s hands-on entrepreneurial expertise contributes to the platform's global leadership in company building.


The Sofinnova Crossover Strategy supports ground-breaking innovations in later-stage biotech and medtech companies, enabling ambitious life sciences companies to reach their full potential.

SofinnovaIndustrial Biotech

Our Industrial Biotech Strategy seeks early-stage investments that will have a positive impact on sustainability in the chemicals, agriculture, food and materials sectors.


The Sofinnova Telethon Strategy seeks early-stage projects to bring the best Italian science to the world stage.

SofinnovaDigital Medicine

The Sofinnova Digital Medicine Strategy backs early-stage startups at the intersection of biology, data and computation.


The Sofinnova Biovelocita Strategy is dedicated entirely to the creation and acceleration of European biotech startups, in partnership with leading research organizations.

Join our mailing list

Keep up to date with our latest news.

Thanks for submitting the form. You are now subscribed to Sofinnova Partners news alerts.An error happened. Please try again later.